{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:58:47Z","timestamp":1787630327108,"version":"build-2736575974"},"reference-count":52,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objective: Pulmonary involvement in systemic sclerosis (SSc) is typically assessed using pulmonary function tests (PFTs), high-resolution CT (HRCT), and composite indices. Patient-reported outcomes (PRO), including ScleroID, provide insight into quality of life, but their relationship with clinical measures and role in overall disease assessment remain unclear. To assess the correlation between ScleroID scores and both lung involvement and disease activity\/damage in a cohort of SSc-ILD patients from a large tertiary care center. Methods: Disease activity [European Scleroderma Study Group Activity Index (EScSG-AI), Scleroderma Clinical Trials Consortium Activity Index (SCTC-AI)], disease severity [Medsger severity scale (MSS)], and PRO measure ScleroID were assessed for associations with the extent and severity of SSc-ILD. Results: In 82 patients with SSc-ILD (mean age 56.0 \u00b1 10.8 years; median disease duration 4.2 \u00b1 4.7 years), higher fibrosis extent (&gt;20%) was associated with worse lung function, greater exercise limitation, and higher ScleroID scores, particularly in fatigue, social life, and body mobility domains (all p \u2264 0.03). Patients with &gt;20% fibrosis also had worse NYHA class and Borg scores during 6-MWD (p &lt; 0.001). Cross-sectional correlations showed that ScleroID total and individual domains were negatively associated with FVC% and 6-MWD, and positively with ILD extent on HRCT. Fatigue, social impact, and mobility domains correlated most strongly with disease activity and severity scores, especially in patients with &gt; 20% fibrosis (r = 0.384\u20130.635, all p \u2264 0.016), whereas breathlessness showed minimal associations (r &lt; 0.2). Conclusions: In SSc-ILD, greater lung fibrosis and functional impairment are associated with worse patient-reported quality of life, particularly in fatigue, mobility, and social domains. ScleroID scores reflect both physiological severity and disease burden highlighting its value as a multidimensional outcome measure in patients with more advanced disease.<\/jats:p>","DOI":"10.3390\/diagnostics16010158","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:40:53Z","timestamp":1767602453000},"page":"158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Sclerosis-Associated ILD: Insights and Limitations of ScleroID"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-9111","authenticated-orcid":false,"given":"Cristina","family":"Ni\u021b\u0103","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-1199","authenticated-orcid":false,"given":"Laura","family":"Gro\u0219eanu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Sfanta Maria Clinical Hospital, 011172 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e000782","DOI":"10.1136\/rmdopen-2018-000782","article-title":"Systemic sclerosis: State of the art on clinical practice guidelines","volume":"4","author":"Smith","year":"2019","journal-title":"RMD Open"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alcolea, M.P., Starita Fajardo, G., Pe\u00f1a Rodr\u00edguez, M., Lucena L\u00f3pez, D., Su\u00e1rez Caranto\u00f1a, C., L\u00f3pez Paraja, M., Garc\u00eda de Vicente, A., Viteri-No\u00ebl, A., and Gonz\u00e1lez Garc\u00eda, A. (2025). Advances in the Molecular Mechanisms of Pulmonary Fibrosis in Systemic Sclerosis: A Comprehensive Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262010103"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/micc.12281","article-title":"Nailfold Capillaroscopy and Clinical Applications in Systemic Sclerosis","volume":"23","author":"Smith","year":"2016","journal-title":"Microcirculation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2665-9913(25)00026-8","article-title":"Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: A multicentre observational cohort study","volume":"7","author":"Petelytska","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/rheumatology\/keac557","article-title":"Systemic sclerosis associated interstitial lung disease: A conceptual framework for subclinical, clinical and progressive disease","volume":"62","author":"Roofeh","year":"2023","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","article-title":"Systemic sclerosis interstitial lung disease: Unmet needs and potential solutions","volume":"20","author":"Liakouli","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/rheumatology\/keae110","article-title":"Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis","volume":"63","author":"Parker","year":"2024","journal-title":"Rheumatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","article-title":"The need for a holistic approach for SSc-ILD\u2014Achievements and ambiguity in a devastating disease","volume":"21","author":"Allanore","year":"2020","journal-title":"Respir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/23971983241303655","article-title":"Patient perspectives on educational needs in scleroderma-interstitial lung disease","volume":"10","author":"Savvaides","year":"2025","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Boleto, G., Santiago, T., and Sieiro Santos, C. (2025). Editorial: Advances in understanding and managing systemic sclerosis-associated interstitial lung disease: Bridging prognostic biomarkers to therapeutic innovations. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1683554"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard.62.9.901","article-title":"European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria","volume":"62","author":"Valentini","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/art.42939","article-title":"Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index","volume":"76","author":"Ross","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_15","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: Development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George\u2019s Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000363","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King\u2019s Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference","volume":"6","author":"Sinha","year":"2019","journal-title":"BMJ Open Respir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/acr.20591","article-title":"Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-reported outcomes measurement information system 29-item health profile and functional assessment of chronic illness therapy\u2013dyspnea short form","volume":"63","author":"Hinchcliff","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs","volume":"31","author":"Mchorney","year":"1993","journal-title":"Med. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13075-020-02329-2","article-title":"Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: An analysis from the EUSTAR database","volume":"22","author":"Allanore","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_21","first-page":"49","article-title":"Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease","volume":"37","author":"Fisher","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/rheumatology\/kep284","article-title":"Minimally important differences in the Mahler\u2019s Transition Dyspnoea Index in a large randomized controlled trial\u2014Results from the Scleroderma Lung Study","volume":"48","author":"Khanna","year":"2009","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","article-title":"Minimal important difference of the transition dyspnoea index in a multinational clinical trial","volume":"21","author":"Witek","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/23971983251318827","article-title":"Quality of life in scleroderma-related interstitial lung disease and its association with respiratory clinical parameters","volume":"10","author":"Ponniah","year":"2025","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_28","unstructured":"(2025, September 23). Orphanet: ATHENA-SSc-ILD: A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)-PL. Available online: http:\/\/www.orpha.net\/en\/research-trials\/clinical-trial\/674705?country=&mode=&name=&recruiting=0&terminated=0."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2021-220702","article-title":"Development and validation of a patient-reported outcome measure for systemic sclerosis: The EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire","volume":"81","author":"Becker","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e005999","DOI":"10.1136\/rmdopen-2025-005999","article-title":"Cross-validation and sensitivity to change of EULAR ScleroID as a measure of function and impact of disease in patients with systemic sclerosis","volume":"11","author":"Colak","year":"2025","journal-title":"RMD Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Antoniou, K.M., Distler, O., Gheorghiu, A.M., Moor, C.C., Vikse, J., Bizymi, N., Galetti, I., Brown, G., Bargagli, E., and Allanore, Y. (Ann. Rheum. Dis., 2025). ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG), Ann. Rheum. Dis., in press.","DOI":"10.1016\/j.ard.2025.08.021"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Khanna","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner Society: Glossary of Terms for Thoracic Imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows","volume":"6","author":"Quanjer","year":"1993","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.jacc.2018.07.068","article-title":"Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients with Systemic Sclerosis","volume":"72","author":"Andreassen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Humbert","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD)\u2014Report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/rheumatology\/keac576","article-title":"Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: Analysis by region","volume":"62","author":"Lescoat","year":"2023","journal-title":"Rheumatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2021-eular.1067","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Allanore","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/annrheumdis-2018-eular.6368","article-title":"AB0787 The eular systemic sclerosis impact of disease (SCLEROID) score\u2014A new patient-reported outcome measure for patients with systemic sclerosis","volume":"77","author":"Dobrota","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002). ATS Statement: Guidelines for the Six-Minute Walk Test. Am. J. Respir. Crit. Care Med., 166, 111\u2013117.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-025-03136-6","article-title":"Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: Data from the ILD-PRO registry","volume":"26","author":"Swaminathan","year":"2025","journal-title":"Respir. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2023","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25914","DOI":"10.31083\/RCM25914","article-title":"Cardiopulmonary Exercise Testing: Deciphering Cardiovascular Complications in Systemic Sclerosis","volume":"26","author":"Giubertoni","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e003426","DOI":"10.1136\/rmdopen-2023-003426","article-title":"Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: A systematic literature review","volume":"9","author":"Petelytska","year":"2023","journal-title":"RMD Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/acr.24122","article-title":"Fatigue and Its Association with Social Participation, Functioning, and Quality of Life in Systemic Sclerosis","volume":"73","author":"Murphy","year":"2021","journal-title":"Arthritis Care Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.rdc.2016.01.003","article-title":"Patient-Reported Outcome Measures in Systemic Sclerosis (Scleroderma)","volume":"42","author":"Pellar","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12931-025-03375-7","article-title":"The importance of considering progression speed in systemic sclerosis\u2014Associated interstitial lung diseases: Application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study","volume":"26","author":"Roeser","year":"2025","journal-title":"Respir. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00296-025-05934-z","article-title":"The association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: An observational study with artificial intelligence analysis of high-resolution computed tomography","volume":"45","author":"Hoffmann","year":"2025","journal-title":"Rheumatol. Int."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/1\/158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:49:49Z","timestamp":1767602989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/1\/158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diagnostics16010158"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16010158","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}